Indicated for: cancer
Route of administration: infusion
Substance: vinflunine (antineoplastic agent)
ATC: L01CA05 (Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Vinca alkaloids and analogues)
Vinflunine is a chemotherapy medication primarily used for the treatment of advanced or metastatic urothelial cancer, particularly in patients who have not responded to other platinum-based therapies. It belongs to the vinca alkaloid class and works by inhibiting tubulin polymerization, leading to the arrest of cell division and ultimately tumor cell death.
Vinflunine is administered intravenously, usually once every three weeks, and the dosage is adjusted based on body weight and the patient's overall condition. Treatment is conducted under the supervision of an oncologist, and patients are monitored for signs of toxicity.
Common side effects include fatigue, nausea, vomiting, constipation, anemia, and neutropenia. In rare cases, severe adverse reactions such as peripheral neuropathy or liver function impairment may occur.
Vinflunine represents an important option for patients with advanced urothelial cancer, offering a chance to control disease progression and improve their quality of life.